M28 Capital Management LP
13F Reported Value
ⓘ$53.8M
Holdings
9
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
M28 Capital Management LP disclosed 9 positions worth $53.8M in its Form 13F-HR for Q1 2026, led by $WVE (Wave Life Sciences Ltd.) at 61.8% of the equity portfolio, followed by $IVVD and $TGTX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from M28 Capital Management LP’s Form 13F-HR filing with the SEC under CIK 1807489.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$33.3M4,588,284 sh - 25.7#2,535
Quality
$12.0M9,248,250 sh - 68.4#417
Quality
$2.9M88,354 sh - 74.4
Quality
$2.3M36,851 sh - —
Quality
$971.7K599,793 sh - —
Quality
$849.7K1,856,117 sh - —
Quality
$754.9K210,871 sh - —
Quality
$533.3K101,203 sh - —
Quality
$155.9K284,889 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Wave Life Sciences Ltd.$WVE | — | $33.3M | 4,588,284 |
 Invivyd, Inc.$IVVD | 25.7#2,535 | $12.0M | 9,248,250 |
 TG THERAPEUTICS, INC.$TGTX | 68.4#417 | $2.9M | 88,354 |
 ARROWHEAD PHARMACEUTICALS, INC.$ARWR | 74.4 | $2.3M | 36,851 |
 ProQR Therapeutics N.V.$PRQR | — | $971.7K | 599,793 |
 FRACTYL HEALTH, INC.$GUTS | — | $849.7K | 1,856,117 |
 ROCKET PHARMACEUTICALS, INC.$RCKT | — | $754.9K | 210,871 |
 Silence Therapeutics plc$SLN | — | $533.3K | 101,203 |
 CURIS INC$CRIS | — | $155.9K | 284,889 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of M28 Capital Management LP's 9 positions.
Showing top 9 of 9 holdings.
Sector Allocation
Healthcare
$53.8M
Full Holdings — M28 Capital Management LP (Q1 2026)
All 9 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $WVE | Wave Life Sciences Ltd. | $33.3M | 61.8% | -19% | — |
| 2 | $IVVD | Invivyd, Inc. | $12.0M | 22.4% | +0% | 25.7 |
| 3 | $TGTX | TG THERAPEUTICS, INC. | $2.9M | 5.5% | -45% | 68.4 |
| 4 | $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $2.3M | 4.3% | -45% | 74.4 |
| 5 | $PRQR | ProQR Therapeutics N.V. | $971,665 | 1.8% | -41% | — |
| 6 | $GUTS | FRACTYL HEALTH, INC. | $849,730 | 1.6% | +0% | — |
| 7 | $RCKT | ROCKET PHARMACEUTICALS, INC. | $754,918 | 1.4% | -45% | — |
| 8 | $SLN | Silence Therapeutics plc | $533,340 | 1.0% | -45% | — |
| 9 | $CRIS | CURIS INC | $155,920 | 0.3% | -45% | — |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for M28 Capital Management LP including:
Track M28 Capital Management LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for M28 Capital Management LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: M28 Capital Management LP
13F Pro is an AI hedge fund tracker and stock research platform. For M28 Capital Management LP (SEC CIK: 1807489), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in M28 Capital Management LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.